Compare PSFE & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSFE | SIGA |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United Kingdom | United States |
| Employees | 2900 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.8M | 341.0M |
| IPO Year | N/A | 2016 |
| Metric | PSFE | SIGA |
|---|---|---|
| Price | $9.11 | $4.67 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.69 | N/A |
| AVG Volume (30 Days) | 316.9K | ★ 517.0K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.15 | N/A |
| Revenue Next Year | $6.25 | $224.81 |
| P/E Ratio | ★ N/A | $14.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $4.29 |
| 52 Week High | $16.49 | $9.62 |
| Indicator | PSFE | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 45.72 |
| Support Level | $6.61 | $4.29 |
| Resistance Level | $9.39 | $4.80 |
| Average True Range (ATR) | 0.39 | 0.12 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 59.58 | 66.67 |
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company's reportable segments are Merchant Solutions and Digital Wallets. The Merchant Solutions segment, which derives maximum revenue, services markets in North America, Canada and Europe. The Digital Wallets segment services markets in Europe, UK, North America and Latin America. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.